Head-to-head dispatch
OurView Health vs Sunlight
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications.
Marked down on: A comparison table on the site quotes $90 'without membership' against $75 'with membership' while the product cards say 'No membership' and the cart charges $75 without one — the provider contradicts itself on whether a membership exists
Desk Score
A LegitScript-certified compounded GLP-1 telehealth brand with flat, openly published pricing — semaglutide from $88/mo, tirzepatide from $157/mo — plus a separate peptide-therapy program (NAD+, and per the live site, sermorelin) under its own intake.
Marked down on: Injectable only for GLP-1 — no oral tablet route on semaglutide or tirzepatide, despite a generic "Injections and oral options available" line in one landing page's hero that matches nothing else on the site
Sunlight takes this head-to-head with the higher Desk Score, 84/100 (B) against 61/100 (C) for OurView Health. OurView Health still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
OurView Health
61/100
C
Sunlight
84/100
B
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | OurView Health | Sunlight |
|---|---|---|
| Semaglutide | $75/mo (starting dose, compounded) | Starts at $88/mo (compounded, injection) |
| Tirzepatide | $135/mo (starting dose, compounded) | Starts at $157/mo (compounded, injection) |
| Coverage | Coverage not published | All 50 states (varies by provider licensure) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Readers who want budget shoppers wanting low-cost compounded GLP-1 via a membership savings model. | Patients who want the lowest published entry price in the ranking and are comfortable with an injection-only compounded program, and don't need an oral or brand-name route. |
| Desk Score | 61/100C | 84/100B |
The verdict
Desk pick — SunlightSunlight takes this head-to-head with the higher Desk Score, 84/100 (B) against 61/100 (C) for OurView Health. OurView Health still holds its ground where its strengths line up with yours.
Choose OurView Health if…
Readers who want budget shoppers wanting low-cost compounded GLP-1 via a membership savings model.
$75/mo (starting dose, compounded) sema · $135/mo (starting dose, compounded) tirz · Coverage not published
Choose Sunlight if…
Patients who want the lowest published entry price in the ranking and are comfortable with an injection-only compounded program, and don't need an oral or brand-name route.
Starts at $88/mo (compounded, injection) sema · Starts at $157/mo (compounded, injection) tirz · All 50 states (varies by provider licensure)
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: OurView Health · Sunlight.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- OurView Health vs CoreAge Rx
- Sunlight vs Vaylen
- OurView Health vs Strut Health
- Sunlight vs Ondra Health
- OurView Health vs Invigor Medical
- Sunlight vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.